



March 26, 2024

Maine Molecular Quality Controls, Inc.
Joan Gordon
President
23 Mill Brook Rd
Saco, Maine 04072

Re: K233611

Trade/Device Name: SPOTFIRE RSP Pos & Neg Controls (M425), SPOTFIRE RSP Positive Control (M42638), SPOTFIRE RSP Negative Control (M42738)

Regulation Number: 21 CFR 866.3920

Regulation Name: Assayed Quality Control Material For Clinical Microbiology Assays

Regulatory Class: Class II

Product Code: PMN

Dated: November 3, 2023

Received: November 13, 2023

Dear Joan Gordon:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

(<https://www.fda.gov/media/99812/download>) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (<https://www.fda.gov/media/99785/download>).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Joseph Briggs-S

Joseph Briggs
Deputy Branch Chief
Division of Microbiology Devices
OHT7: Office of In Vitro Diagnostics
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K233611

Device Name

SPOTFIRE RSP Pos & Neg Controls (M425);

SPOTFIRE RSP Positive Control (M42638);

SPOTFIRE RSP Negative Control (M42738)

Indications for Use (Describe)

SPOTFIRE RSP Positive Control:

SPOTFIRE® RSP Positive Control is intended for use (as applicable) as an external positive assayed quality control to monitor performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of *Bordetella parapertussis*, *Bordetella pertussis*, *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, *Streptococcus dysgalactiae* (Group C/G Strep), *Streptococcus pyogenes* (Group A Strep), Adenovirus, Coronavirus SARS-CoV-2, Coronavirus (seasonal), Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A Subtype H1-2009, Influenza A Subtype H3, Influenza B, Parainfluenza Virus and Respiratory Syncytial Virus using the BIOFIRE® SPOTFIRE Respiratory (R) Panel, BIOFIRE SPOTFIRE Respiratory (R) Panel Mini, and BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel on the BIOFIRE SPOTFIRE System. SPOTFIRE RSP Positive Control is comprised of in vitro RNA transcripts and stabilizing solution and is designed for and intended to be used solely with the BIOFIRE SPOTFIRE R Panel, BIOFIRE SPOTFIRE R Panel Mini, and BIOFIRE SPOTFIRE R/ST Panel assays. This product is not intended to replace manufacturer internal controls provided with these devices.

Quality control materials should be used in accordance with local, state, federal regulations, and accreditation requirements.

SPOTFIRE RSP Negative Control:

SPOTFIRE® RSP Negative Control is intended for use (as applicable) as an external negative assayed quality control to monitor performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of *Bordetella parapertussis*, *Bordetella pertussis*, *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, *Streptococcus dysgalactiae* (Group C/G Strep), *Streptococcus pyogenes* (Group A Strep), Adenovirus, Coronavirus SARS-CoV-2, Coronavirus (seasonal), Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A Subtype H1-2009, Influenza A Subtype H3, Influenza B, Parainfluenza Virus and Respiratory Syncytial Virus using the BIOFIRE® SPOTFIRE Respiratory (R) Panel, BIOFIRE SPOTFIRE Respiratory (R) Panel Mini, and BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel on the BIOFIRE SPOTFIRE System. SPOTFIRE RSP Negative Control is comprised of a solution that does not contain target analytes and is designed for and intended to be used solely with the BIOFIRE SPOTFIRE R Panel, BIOFIRE SPOTFIRE R Panel Mini, and BIOFIRE SPOTFIRE R/ST Panel assays. This product is not intended to replace manufacturer internal controls provided with these devices.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



Section 5: 510 (k) Summary

510(k) Number:

Purpose for submission: Change to existing device (reference K230868) to include the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel (SPOTFIRE R/ST Panel) in the intended use for SPOTFIRE RSP Pos & Neg Controls.

Applicant Information:

Applicant: Maine Molecular Quality Controls, Inc.
Address: 23 Mill Brook Road
Saco, Maine 04072
Contact Person: Joan Gordon, President MMQCI
Phone: 207-885-1072 extension 201
Fax: 207-885-1079
Email Address: jgordon@mmqci.com

Preparation Date: March 19, 2024

Device

Device Trade Name: SPOTFIRE RSP Pos & Neg Controls, model M425
SPOTFIRE RSP Positive Control, model M42638
SPOTFIRE RSP Negative Control, model M42738
Device Common Name: Quality Control Material for Microbiology Assays
Device Type: Assayed quality control material for clinical microbiology assays
Class: Class II (Special controls)
Regulation: 21 CFR 866.3920
Panel: Microbiology - 83
Product code: PMN

Predicate Device

K230868 SPOTFIRE RSP Pos & Neg Controls
SPOTFIRE RSP Positive Control
SPOTFIRE RSP Negative Control

Proposed Change:

The specific change to the existing device is the inclusion of the SPOTFIRE R/ST Panel in the intended use for SPOTFIRE RSP Pos & Neg Controls, with subsequent updates of the Indications of Use (FDA Form 3881), Package Inserts for SPOTFIRE RSP Positive Control and



SPOTFIRE RSP Negative Control, and the addition of data for SPOTFIRE R/ST Panel analytes *Streptococcus dysgalactiae* (Group C/G Strep) and *Streptococcus pyogenes* (Group A Strep) to this submission. No other changes have been made to the original device referenced in K230868.

Description of Modified Device (inclusion of use with SPOTFIRE R/ST Panel)

SPOTFIRE RSP Pos & Neg Controls, P/N M425, is a quality control panel consisting of 2 ready-to-use, liquid controls, SPOTFIRE RSP Positive Control (Positive Control), P/N M42638 and SPOTFIRE RSP Negative Control (Negative Control), P/N M42738. The Positive Control contains non-infectious surrogate control material; a solution of synthetic RNA transcripts in buffer, stabilizers and preservatives. The RNA in the Positive Control carries RNA segments of all the respiratory and sore throat pathogens detected by the BIOFIRE SPOTFIRE Respiratory (R) Panel, BIOFIRE SPOTFIRE Respiratory (R) Panel Mini, and BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel assays, performed on the BIOFIRE SPOTFIRE System. (see **Tables 1-3** below) SPOTFIRE RSP Pos & Neg Controls are specifically designed for and intended to be used solely with the BIOFIRE SPOTFIRE R Panel, BIOFIRE SPOTFIRE R Panel Mini, and BIOFIRE SPOTFIRE R/ST Panel assays on the BIOFIRE SPOTFIRE System. The Negative Control contains buffer and preservatives with no RNA. Each liquid control of SPOTFIRE RSP Pos & Neg Controls is processed separately according to the SPOTFIRE Panel assay manufacturer's Instructions for Use for patient samples (nasopharyngeal swabs or throat swabs placed in transport media) obtained from individuals with signs and symptoms of respiratory tract infection or pharyngitis.

Table 1. Respiratory pathogens detected by BIOFIRE SPOTFIRE R Panel

Viruses	Bacteria
Adenovirus	<i>Chlamydia pneumoniae</i>
Coronavirus SARS-CoV-2	<i>Mycoplasma pneumoniae</i>
Coronavirus (seasonal)	<i>Bordetella parapertussis</i>
Human Metapneumovirus	<i>Bordetella pertussis</i>
Human Rhinovirus/ Enterovirus	
Influenza A Virus	
Influenza A virus A/H1-2009	
Influenza A virus A/H3	
Influenza B Virus	
Parainfluenza	
Respiratory Syncytial Virus	

Table 2. Respiratory viruses detected by the BIOFIRE SPOTFIRE R Panel Mini

Coronavirus SARS-CoV-2
Human Rhinovirus
Influenza A Virus
Influenza B Virus
Respiratory Syncytial Virus

Table 3. Respiratory and sore throat pathogens detected by BIOFIRE SPOTFIRE R/ST Panel

Viruses (Respiratory and Sore Throat)	Bacteria (Respiratory and Sore Throat)
Adenovirus	<i>Chlamydia pneumoniae</i>
Coronavirus SARS-CoV-2	<i>Mycoplasma pneumoniae</i>
Coronavirus (seasonal)	Bacteria (Respiratory Only)
Human Metapneumovirus	<i>Bordetella parapertussis</i>
Human Rhinovirus/ Enterovirus	<i>Bordetella pertussis</i>
Influenza A Virus	Bacteria (Sore Throat Only)
Influenza A virus A/H1-2009	<i>Streptococcus dysgalactiae</i> (group C/G Strep)
Influenza A virus A/H3	<i>Streptococcus pyogenes</i> (group A Strep)
Influenza B Virus	
Parainfluenza	
Respiratory Syncytial Virus	

Intended Use of SPOTFIRE RSP Pos & Neg Controls modified to include the addition SPOTFIRE R/ST Panel

SPOTFIRE RSP Positive Control:

SPOTFIRE RSP Positive Control is intended for use (as applicable) as an external positive assayed quality control to monitor performance of *in vitro* laboratory nucleic acid testing procedures for the qualitative detection of *Bordetella parapertussis*, *Bordetella pertussis*, *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, *Streptococcus dysgalactiae* (Group C/G Strep), *Streptococcus pyogenes* (Group A Strep), Adenovirus, Coronavirus SARS-CoV-2, Coronavirus (seasonal), Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A Subtype H1-2009, Influenza A Subtype H3, Influenza B, Parainfluenza Virus, and Respiratory Syncytial Virus using the BIOFIRE SPOTFIRE Respiratory (R) Panel, BIOFIRE SPOTFIRE Respiratory (R)



Panel Mini, and BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel on the BIOFIRE SPOTFIRE System. SPOTFIRE RSP Positive Control is comprised of *in vitro* RNA transcripts and stabilizing solution and is designed for and intended to be used solely with the BIOFIRE SPOTFIRE R Panel, BIOFIRE SPOTFIRE R Panel Mini, and BIOFIRE SPOTFIRE R/ST Panel assays. This product is not intended to replace manufacturer internal controls provided with these devices.

Quality control materials should be used in accordance with local, state, federal regulations, and accreditation requirements.

SPOTFIRE RSP Negative Control:

SPOTFIRE RSP Negative Control is intended for use (as applicable) as an external negative assayed quality control to monitor performance of *in vitro* laboratory nucleic acid testing procedures for the qualitative detection of *Bordetella parapertussis*, *Bordetella pertussis*, *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, *Streptococcus dysgalactiae* (Group C/G Strep), *Streptococcus pyogenes* (Group A Strep), Adenovirus, Coronavirus SARS-CoV-2, Coronavirus (seasonal), Human Metapneumovirus, Human Rhinovirus/Enterovirus, Influenza A Subtype H1-2009, Influenza A Subtype H3, Influenza B, Parainfluenza Virus, and Respiratory Syncytial Virus using the BIOFIRE SPOTFIRE Respiratory (R) Panel, BIOFIRE SPOTFIRE Respiratory (R) Panel Mini, and BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel on the BIOFIRE SPOTFIRE System. SPOTFIRE RSP Negative Control is comprised of a solution that does not contain target analytes and is designed for and intended to be used solely with the BIOFIRE SPOTFIRE R Panel, BIOFIRE SPOTFIRE R Panel Mini, and BIOFIRE SPOTFIRE R/ST Panel assays. This product is not intended to replace manufacturer internal controls provided with these devices.

Quality control materials should be used in accordance with local, state, federal regulations, and accreditation requirements.

Substantial Equivalence

Maine Molecular Quality Controls, Inc. (MMQCI) proposes that the changes made to the labeling of SPOTFIRE RSP Pos & Neg Controls to include the additional intended use of SPOTFIRE R/ST Panel do not impact substantial equivalence to SPOTFIRE RSP Pos & Neg Controls (K230868). There have been no changes to the predicate device, other than labeling. The rationale for equivalence is listed in **Table 4** below.

Table 4. Substantial Equivalence of Predicate Devices

Characteristic	Candidate Device: SPOTFIRE RSP Pos & Neg Controls	Predicate Device: SPOTFIRE RSP Pos & Neg Controls (K230868)
Intended Use	External assayed quality control to monitor <i>in vitro</i> lab nucleic acid test using the SPOTFIRE R Panel, SPOTFIRE R Panel Mini, and SPOTFIRE R/ST Panel performed on the SPOTFIRE System.	Original 510(k) IFU did not include the SPOTFIRE R/ST Panel
Labeling	SPOTFIRE R/ST Panel added to the Package Insert, no changes to Kit or Tube labels.	SPOTFIRE R/ST Panel not included in Package Insert
Physical format	Ready-to-Use Liquid	Same
Directions for Use	Process like patient sample	Same
Composition	Synthetic RNA transcripts	Same
Assay steps monitored	Reverse transcription, amplification, detection, identification	Same
Test System	SPOTFIRE	Same
Number of targets monitored in one assay	Multiple	Original 510(k) data did not include the sore throat targets detected by SPOTFIRE R/ST Panel
Pathogens contained in the control panel	Respiratory and Sore Throat	Respiratory
User	Non-lab (CLIA Waived) and lab professionals (CLIA certified)	Same

Summary of Performance Data

Three lots of SPOTFIRE RSP Pos & Neg Controls were manufactured by MMQCI at MMQCI's facility in Saco, Maine. The lots were manufactured and tested such that routine variables,



including lots of key manufacturing components, different operators, pouch lots, instruments, test sites, and testing over time were incorporated to challenge manufacture processes and product performance. External and internal studies were performed by testing the 3 lots with the SPOTFIRE R/ST Panel assay on the SPOTFIRE System (BioFire Diagnostics) to generate a total of 361 test results.

For the external performance study, 5 near-patient clinical sites tested samples of each of the 3 lots of SPOTFIRE RSP Positive Controls and SPOTFIRE RSP Negative Controls as they would test controls during normal operations, using 25 SPOTFIRE R/ST Panel pouch lots, incorporating multiple operators and instruments for a total of 232 tests, including 7 Invalid results which were repeated. The internal study was performed by testing samples of each of the 3 SPOTFIRE RSP Pos & Neg Controls lots at MMQCI (Saco, Maine) on different days with 3 pouch lots by 3 operators for a total of 129 tests (3 Invalid results were repeated). One of the pouch lots used at the MMQCI site was also used at a clinical site.

Results and Conclusions:

Of the total 361 tests performed, there were 10 Invalid results which repeated for 351 valid test results. The Invalid results included instrument errors (3) and failed internal pouch controls (7). The Invalid samples were re-tested according to BioFire instructions and were not included in the Percent Correct analysis in **Table 5** below. Of the 351 valid results, 350 results were correct. One SPOTFIRE RSP Positive Control failed due to false negative results for 4 analytes.

Reproducibility of SPOTFIRE RSP Pos & Neg Controls at 6 sites, across 27 pouch lots, 3 control lots, on multiple instruments by multiple operators is acceptable according to predetermined criteria with an overall correct result rate of 99.7%. Test results demonstrate robust performance across 6 testing sites.

Table 5. SPOTFIRE RSP Pos & Neg Controls: Reproducibility results, all sites.

Summary of Reproducibility Test Results: External and Internal Sites								
Total Tests	Invalid*	Correct Positive Control Result	Incorrect Positive Control Result	Percent Correct Positive Control	Correct Negative Control Result	Incorrect Negative Control Result	Percent Correct Negative Control	Total Percent Correct
361	10	171	1	99.3%	179	0	100%	99.7%

*The Invalid samples were not included in the Percent Correct analysis.

External Site Testing Details

A total of 232 samples of SPOTFIRE RSP Positive and RSP Negative Controls were tested at 5 near-patient clinical sites. The sites were asked to follow the SPOTFIRE R/ST Panel IUO Quick Guide to run the controls as they would during normal operations, e.g. training a new operator, receiving new shipments of R/ST Panel test kits, receiving new or repaired instrumentation, and



whenever the test kits have been stored at an incorrect temperature. It was recommended a negative quality control sample be run at least monthly to monitor for environmental contamination. The amount of QC a site performed was based on the number of operators they had and the amount of SPOTFIRE R/ST Panel testing their site performed.

Three lots of SPOTFIRE RSP Positive Control (A02NOV20, B06NOV20, C10NOV20) and 4 lots of SPOTFIRE RSP Negative Control (F09JUL19, D11MAR20, H05MAY20, C13MAY20) were tested on 25 SPOTFIRE R/ST Panel pouch lots across the 5 sites, incorporating multiple operators and instruments. Of the 232 samples tested, there were 7 Invalid results which were repeated for a total of 225 valid results. Of the 7 Invalid results, 4 were failed internal pouch controls and 3 were due to instrument errors.

Results and Conclusion:

Out of 225 tests with valid results, the correct analytes were detected (for positive controls) or not detected (for negative controls) in 224 tests, for an overall success rate of 99.6% (**Table 5**). One SPOTFIRE RSP Positive Control failed due to false negative results for 4 analytes. The predetermined acceptance criteria for reproducibility were met. SPOTFIRE RSP Positive Control and RSP Negative Control performed robustly at the 5 external test sites across 25 pouch lots on the SPOTFIRE System, incorporating multiple operators.

Table 5. Summary of External Reproducibility Results for 3 Control Lots at 5 Clinical Sites

Summary of External Results for 3 Lots of SPOTFIRE RSP Pos & Neg Controls									
Site	Total Tests	Invalid	Correct Positive Control Result	Incorrect Positive Control Result	Percent Correct Positive Control	Correct Negative Control Result	Incorrect Negative Control Result	Percent Correct Negative Control	Total Percent Correct
1	26	0	13	0	100%	13	0	100%	100%
2	33	1	13	0	100%	19	0	100%	100%
3	120	4	53	1	98.1%	62	0	100%	99.1%
4	44	1	21	0	100%	22	0	100%	100%
5	9	1	8	0	100%	NA	NA	NA	NA
All Sites	232	7*	108	1	99.1%	116	0	100%	99.6%

*Invalid results were not included in percent correct.

Internal Site Testing Details

Run-to-run Precision Testing at MMQCI: Of the total 361 reproducibility tests, 129 SPOTFIRE RSP Positive Control and SPOTFIRE RSP Negative Control samples were tested on 21 different days at MMQCI's facility in Saco, Maine. Three lots of Positive Control (A02NOV20, B06NOV20, C10NOV20) and 3 lots of Negative Control (F09JUL19, D11MAR20, H05MAY20)



were tested on 3 SPOTFIRE R/ST pouch lots, incorporating 4 operators and 1 SPOTFIRE instrument (**Table 6**). One of the pouch lots was also used for the external site testing.

Results and conclusions:

Of the 129 results, 3 were Invalid which were repeated for a total of 126 valid results. All 126 of the valid results were correct for an overall correct result rate of 100%. Predetermined acceptance criteria for reproducibility were met. SPOTFIRE RSP Positive Control and SPOTFIRE RSP Negative Control performed robustly on 21 different days at MMQCI across 3 pouch lots on 1 SPOTFIRE instrument, incorporating 4 operators.

Table 6. SPOTFIRE RSP Pos & Neg Controls: Reproducibility results at MMQCI.

Summary of Precision Testing for 3 RSP Control Lots at MMQCI						
Control	Control Lot #	No. of Tests	Invalid*	Correct Results	Incorrect Results	Percent Correct
SPOTFIRE RSP Positive Control	A02NOV20	23	2	21	0	100%
SPOTFIRE RSP Positive Control	B06NOV20	21	0	21	0	100%
SPOTFIRE RSP Positive Control	C10NOV20	22	1	21	0	100%
SPOTFIRE RSP Negative Control	F09JUL19	21	0	21	0	100%
SPOTFIRE RSP Negative Control	D11MAR20	21	0	21	0	100%
SPOTFIRE RSP Negative Control	H05MAY20	21	0	21	0	100%
*Invalid results were not included in percent correct.	TOTAL	129	3	126	0	100%

Overall Conclusion

The above information supports the substantial equivalence of the SPOTFIRE RSP Positive and Negative Controls to the predicate device.